|Daily Range||$36.85 - $36.99|
|52-Week Range||$31.58 - $38.71|
|Dividend (Yield)||$0.00 (2.5%)|
|Average Daily Volume||544,365|
|Current FY EPS||$2.04|
News & Commentary
Exelixis stock got mauled after its lead drug failed to impress in a key late-stage study. Find out whether there's any hope left for this biotech stock or if it's time for investors to kiss it goodbye.
Cancer immunotherapy vaccine developer Inovio Pharmaceuticals has largely underperformed the market in 2014. Find out what's keeping the stock down and whether or not Inovio shares are poised for a rebound.
Of the seven most common types of cancer, melanoma incidence was the only one to rise between 2000 and 2009. Find out in which seven states melanoma occurs most often, as well as what's being done to curb this terrible form of skin cancer.
Exelixis' stock is among today's biggest losers after its late-stage prostate cancer trial failed to meet its primary endpoint. See what shareholders should be focused on going forward.
Successful new drug launches have fueled Johnson & Johnson's run, but is there enough left in the tank for shares to continue heading higher?
Exelixis stock takes one on the chin after the company's lead compound fails to provide a statistically significant survival benefit in a late stage prostate cancer trial. Find out what's next for this highly-followed biotech stock.
Roche stuns Wall Street and investors by snatching up InterMune and its first-in-class lung disease drug. But, does this deal make sense?
Roche continues to build upon the strongest oncology franchise in Big Pharma but could still use some non-oncology hits
The company's tablet, Zydelig, works by blocking signals inside some cancer cells that allow them to grow and survive.
Pfizer gives Puma Biotechnology a gift, while Puma might be able to steal sales from Roche.